IOBT (IO Biotech) Total Inventories : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is IO Biotech Total Inventories?

IO Biotech's total inventories for the quarter that ended in Sep. 2024 was $0.00 Mil. IO Biotech's average total inventories from the quarter that ended in Jun. 2024 to the quarter that ended in Sep. 2024 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. IO Biotech's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was $0.95.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

IO Biotech Total Inventories Historical Data

The historical data trend for IO Biotech's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IO Biotech Total Inventories Chart

IO Biotech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

IO Biotech Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Inventories	Get a 7-Day Free Trial														-	-	-	-	-

IO Biotech Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

IO Biotech (NAS:IOBT) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

IO Biotech's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is

	Net-Net Working Capital Per Share (Q: Sep. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(80.185	+	0.75 * 0	+	0.5 * 0	-	17.38
-	0	-	0)	/	65.8809
=	0.95

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

IO Biotech's Days Inventory for the three months ended in Sep. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2024 )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

IO Biotech's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2024 )	/	Average Total Inventories (Q: Sep. 2024 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

IO Biotech's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

IO Biotech Total Inventories Related Terms

Thank you for viewing the detailed overview of IO Biotech's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

IO Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IO Biotech Inc (NAS:IOBT) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen N, DNK, DK-2200

Website

https://www.iobiotech.com

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Executives

Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Brian Burkavage	officer: Chief Accounting Officer	C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103
Heidi Hunter	director	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Partners Kurma	10 percent owner	24 RUE ROYALE, PARIS I0 75008
Vivo Opportunity Fund Holdings, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Devin Whittemore Smith	officer: General Counsel	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Vivo Capital Fund Ix, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Qasim Iftikhar Ahmad	officer: Chief Medical Officer	1209 ORANGE STREET, WILMINGTON DE 19801
Amy Sullivan	officer: Chief Financial Officer	38 OUTLOOK ROAD, SWAMPSCOTT MA 01907
David V Smith	director	6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Lundbeckfond Invest A/s	10 percent owner	SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100
Jack Nielsen	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vanessa Malier	director	1209 ORANGE STREET, WILLMINGTON DE 19801
Claus A. Andersson	director	1209 ORANGE STREET, WILMINGTON DE 19801